Anaptysbio (ANAB) Research & Development (2016 - 2026)
Anaptysbio (ANAB) posted Research & Development of $34.0 million for Q1 2026, up 32.99% on a QoQ basis from $25.6 million in Q4 2025, and down 17.46% year-over-year from $41.2 million in Q1 2025.
Anaptysbio (ANAB) Research & Development (2016 - 2026) Analysis & Trends
Anaptysbio's Research & Development history runs 11 years deep, the most recent figure standing at $34.0 million for Q1 2026.
- Quarterly Research & Development fell 17.46% year-over-year to $34.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $128.8 million (down 23.33% YoY) and the FY2025 annual result came in at $136.0 million, down 17.01% from the prior year.
- Research & Development was $34.0 million for Q1 2026 at Anaptysbio, up from $25.6 million in the prior quarter.
- Across five years, Research & Development topped out at $42.6 million in Q4 2024 and bottomed at $20.8 million in Q2 2022.
- A 5-year average of $32.6 million and a median of $33.5 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development surged 57.95% — and 2025, when it sank 39.99%.
- Anaptysbio's Research & Development stood at $23.4 million in 2022, then jumped by 43.43% to $33.5 million in 2023, then advanced by 27.04% to $42.6 million in 2024, then plunged by 39.99% to $25.6 million in 2025, then surged by 32.99% to $34.0 million in 2026.
- Business Quant data shows ANAB's Research & Development at $34.0 million in Q1 2026, $25.6 million in Q4 2025, and $31.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Anaptysbio | 1.55 Bn | 1.27 Bn | - | 33.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.99 Mn |
| Dec 31, 2025 | 25.56 Mn |
| Sep 30, 2025 | 31.41 Mn |
| Jun 30, 2025 | 37.82 Mn |
| Mar 31, 2025 | 41.18 Mn |
| Dec 31, 2024 | 42.59 Mn |
| Sep 30, 2024 | 42.21 Mn |
| Jun 30, 2024 | 42.00 Mn |
| Mar 31, 2024 | 37.04 Mn |
| Dec 31, 2023 | 33.53 Mn |
| Sep 30, 2023 | 30.88 Mn |
| Jun 30, 2023 | 32.92 Mn |
| Mar 31, 2023 | 34.96 Mn |
| Dec 31, 2022 | 23.37 Mn |
| Sep 30, 2022 | 22.06 Mn |
| Jun 30, 2022 | 20.84 Mn |
| Mar 31, 2022 | 22.52 Mn |
| Dec 31, 2021 | 26.78 Mn |
| Sep 30, 2021 | 22.22 Mn |
| Jun 30, 2021 | 25.31 Mn |